In this Medscape commentary, Dr. Scott Kopetz of MD Anderson unpacks the rising role of ctDNA in colorectal cancer. Unlike traditional risk factors, ctDNA offers a real-time snapshot of tumor biology with powerful prognostic value. From guiding adjuvant therapy decisions in stage 2 and 3 disease to detecting recurrence months before imaging, the test is reshaping how oncologists think about surveillance and trial design. With sensitivity still evolving and novel therapies on the horizon, is ctDNA about to become the new backbone of CRC management?
Trending
- OneOncology and OpenEvidence Partner to Improve Cancer Care Nationwide (OneOncology)
- FIT-Based Screening Linked to Drop in Colorectal Cancer Mortality (Medpage Today)
- Vedanta Biosciences Secures $60 Million in Funding and Strengthens Leadership Team Ahead of Pivotal Phase 3 Data (Business Wire)
- The physician opportunity cost nobody puts on a bill (KevinMD)
- A ‘molecular switch’ that heals the gut—and that colorectal cancer hijacks to spread (Medical Xpress)
- Why gastroenterology is especially exposed to predatory contracts, GI says (Becker’s GI & Endoscopy)
- The Microbiome Is Not a Bar Code
- Not All False-Positive Stool DNA Tests Should be Dismissed (GI & Endoscopy News)
